ESSA Pharma Inc. (EPIX) News

ESSA Pharma Inc. (EPIX): $4.90

0.08 (-1.61%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add EPIX to Watchlist
Sign Up

Filter EPIX News Items

EPIX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

EPIX News Highlights

  • For EPIX, its 30 day story count is now at 5.
  • Over the past 10 days, the trend for EPIX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • ESSA and AR are the most mentioned tickers in articles about EPIX.

Latest EPIX News From Around the Web

Below are the latest news stories about ESSA PHARMA INC that investors may wish to consider to help them evaluate EPIX as an investment opportunity.

These Stocks under $10 Are Poised To Explode

In this piece, we will take a look at these stocks under $10 are poised to explode. If you want to skip our introduction to these tricky stocks, jump to These 5 Stocks Under $10 Are Poised To Explode. The US equity markets remain on track for a strong finish in 2023 as major indices […]

Yahoo | December 21, 2023

EPIX: Initial Data from Combination Trial of Masofaniten and Enzalutamide Expected in 2024…

By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Update on Masofaniten Clinical Programs ESSA Pharma Inc. (NASDAQ:EPIX) is developing masofaniten (EPI-7386), its next-generation antigen molecule that is designed to target the N-terminal domain (NTD) of the androgen receptor (AR) as a treatment for prostate cancer. Masofaniten is currently being evaluated in two

Yahoo | December 20, 2023

EPIX Stock Earnings: ESSA Pharma Beats EPS for Q4 2023

EPIX stock results show that ESSA Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.

InvestorPlace Earnings on InvestorPlace | December 12, 2023

ESSA Pharma Inc (EPIX) Reports Fiscal Q4 and Full-Year Earnings, Advances in Prostate Cancer ...

Corporate Update and Financial Highlights for the Year Ended September 30, 2023

Yahoo | December 12, 2023

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023

ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2023.

Yahoo | December 12, 2023

Bullish ESSA Pharma Insiders Loaded Up On US$1.19m Of Stock

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Yahoo | December 11, 2023

Director Franklin Berger Bolsters Position in ESSA Pharma Inc with Purchase of 23,259 Shares

Recent insider trading activity has caught the attention of market analysts and investors alike, as Director Franklin Berger executed a significant purchase of shares in ESSA Pharma Inc (NASDAQ:EPIX).

Yahoo | November 23, 2023

ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference

ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30, 2023, at 12:00 p.m. ET in New York.

Yahoo | November 21, 2023

ESSA Pharma to Present at the Jefferies London Healthcare Conference

ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Wednesday, November 15, 2023, at 8:30 a.m. GMT/ 3:30 a.m. ET in London.

Yahoo | November 8, 2023

ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement

ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has entered into an Open Market Sale AgreementSM (the "ATM Sales Agreement") with Jefferies LLC, effective as of November 3, 2023. Under the ATM Sales Agreement, ESSA may sell its common shares in the capital of the Company from time to time for up to US$50.0 million in aggregate sales proceeds. No

Yahoo | November 6, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!